LNSR News and Press, LENSAR Inc. From 05/09/22

LENSAR press release (NASDAQ:LNSR): Q1 GAAP EPS of -$0.67 misses by $0.16. Revenue of $9.3M (+32.1% Y/Y) beats by $0.59M. For further details see: LENSAR GAAP EPS of -$0.67 misses by $0.16, revenue of $9.3M beats by $0.59M

First Quarter Revenue Increases 33% Over 2021 Levels First Quarter Procedure Volume Increases 38% Over 2021 Levels LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2022 financial result...

LENSAR press release (NASDAQ:LNSR): Q4 GAAP EPS of -$0.41 beats by $0.03. Revenue of $11.22M (+35.2% Y/Y) beats by $2.32M. For further details see: LENSAR GAAP EPS of -$0.41 beats by $0.03, revenue of $11.22M beats by $2.32M

2021 Revenue Increases $8.1 million or 31% over 2020 Levels Procedure Volume Increases over 2020 Levels by 37% in Fourth Quarter and by 35% in 2021 Cash and Cash Equivalents of $31.6 Million Reflect Cash Utilization of $0.7 Million in the Fourth Quarter LENSAR, I...

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the U.S. Food and Drug Administration (“FDAȁ...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2021 f...

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in two...

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will present at the H.C...

Demonstrates LENSAR Laser’s Ability to Guide Improved Astigmatic Outcomes for Patients LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for...